慢性C型肝炎病毒感染:查和治疗的持续挑战
Wei-Chu Tsai1, Hseuh-Chien Chiang1, Yen-Cheng Chiu1
1Department of Internal Medicine, National Cheng Kung University Hospital, College of Medicine, National Cheng Kung University, Tainan 704, Taiwan.
肝炎C病毒 (HCV) 现在可以用直接作用抗病毒药物 (DAA) 治愈,改善健康结果. 然而,在诊断,治疗和预防再感染方面仍然存在挑战,以实现全球消除目标.
科学领域:
- 肝病学 肝病学是一种肝病学.
- 传染性疾病 传染性疾病
- 公共卫生 公共卫生
背景情况:
- 肝炎C病毒 (HCV) 感染现在可以用直接作用抗病毒药物 (DAA) 治愈.
- 成功清除HCV可以改善肝脏和肝脏外的结果,包括肝硬化并发症,肝细胞癌,心血管疾病和糖尿病.
- 全球HCV消除目标在诊断,治疗联系和遵守方面面临挑战.
研究的目的:
- 审查目前使用DAA治疗HCV的现状.
- 确定在实现HCV消除方面存在的持续挑战.
- 强调DAA治疗作为预防策略的作用.
主要方法:
- 对针对HCV的直接作用抗病毒药物的当前文献的综述.
- 对HCV诊断和治疗策略的挑战进行分析.
- 对治疗后的监测和预防再感染的评估.
主要成果:
- DAA已经将HCV转变为一种可治愈的疾病,具有显著的健康益处.
- 关键的挑战包括识别未被诊断的个体,重新参与患者的护理,并提高高风险群体的治疗率.
- 预防再感染和肝细胞癌监测对于长期有效性至关重要.
结论:
- 用DAA治疗HCV是最有效的预防策略,提供高效率和安全性.
- 战略必须侧重于加强诊断,治疗开始和遵守,以实现世卫组织的消除目标.
- 临床实践应优先考虑DAA治疗和相关监测措施,以持续控制HCV.
更多相关视频
12:24A Three-Dimensional Spheroid Model to Investigate the Tumor-Stromal Interaction in Hepatocellular Carcinoma
Published on: September 30, 2021
11:34A Competent Hepatocyte Model Examining Hepatitis B Virus Entry through Sodium Taurocholate Cotransporting Polypeptide as a Therapeutic Target
Published on: May 10, 2022
相关概念视频
Chronic Kidney Disease I: Introduction
Chronic Pancreatitis II: Collaborative Care
Assessment:
Retrovirus Life Cycles
Esophageal Varices-II: Clinical Features and Management
In the initial assessment, a thorough review of the patient's medical history is vital to identify risk factors such as liver disease, alcohol...
Diseases of the Liver and Gallbladder
Cirrhosis is characterized by the scarring of hepatic lobules in the liver, which are replaced by fibrous tissue, affecting the liver's normal functioning. NAFLD, on the other hand, is caused by an excessive build-up of fat in the liver, not...
Chronic Kidney Disease III: Interprofessional Care
